Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Investing
Why the Australian dollar could climb above US80 cents
⏸️ Investing
4 reasons why CSL Limited is a buy
⏸️ Investing
Why these 4 shares are soaring higher today
⏸️ Investing
Cochlear Limited could be a bargain on today's share price weakness
⏸️ Investing
Earnings Preview: 8 shares to watch this week
⏸️ Investing
Revealed: My favourite ASX healthcare stock to buy now
⏸️ Investing
A value investor's guide to Cochlear Limited
⏸️ Investing
This company looks set to soar over the next 10 years
⏸️ Investing
This is why I am thinking about selling my Cochlear Limited shares
⏸️ Shares to Watch
The top 10 mid cap stocks to add to your watchlist
⏸️ Investing
The easy way to start building a $1 million share portfolio in FY 2017
⏸️ Investing
Is Cochlear Limited a Sell at today's share price?
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
